MonumenTAL Results for Talquetamab in Myeloma.

Cancer discovery 2023 Feb 06

filter terms:

all
biogroup
compound
phenotype
gene and proteins
tissue
show more »
show less «

Nearly three quarters of the 288 patients with relapsed/refractory multiple myeloma enrolled in the phase I/II MonumenTAL-1 trial of the investigational drug talquetamab experienced significant anticancer effects. A first-in-class, off-the-shelf bispecific antibody, talquetamab targets GPRC5D, which is highly expressed on malignant plasma cells but limited on normal cells, and recruits CD3-expressing T cells, activating an immune response. ©2023 American Association for Cancer Research.